JP6810028B2 - 組換え片利共生皮膚微生物による皮膚疾患の治療処置 - Google Patents

組換え片利共生皮膚微生物による皮膚疾患の治療処置 Download PDF

Info

Publication number
JP6810028B2
JP6810028B2 JP2017515014A JP2017515014A JP6810028B2 JP 6810028 B2 JP6810028 B2 JP 6810028B2 JP 2017515014 A JP2017515014 A JP 2017515014A JP 2017515014 A JP2017515014 A JP 2017515014A JP 6810028 B2 JP6810028 B2 JP 6810028B2
Authority
JP
Japan
Prior art keywords
seq
pharmaceutical composition
skin
composition according
filaggrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017515014A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017518370A (ja
JP2017518370A5 (enExample
Inventor
モミン ミューニバー アジム
モミン ミューニバー アジム
マイケル ウィットフィル トラビス
マイケル ウィットフィル トラビス
Original Assignee
アジトラ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アジトラ，インコーポレイティド filed Critical アジトラ，インコーポレイティド
Publication of JP2017518370A publication Critical patent/JP2017518370A/ja
Publication of JP2017518370A5 publication Critical patent/JP2017518370A5/ja
Application granted granted Critical
Publication of JP6810028B2 publication Critical patent/JP6810028B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
JP2017515014A 2014-05-30 2015-05-28 組換え片利共生皮膚微生物による皮膚疾患の治療処置 Active JP6810028B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462005652P 2014-05-30 2014-05-30
US201462005558P 2014-05-30 2014-05-30
US62/005,558 2014-05-30
US62/005,652 2014-05-30
PCT/US2015/032972 WO2015184134A1 (en) 2014-05-30 2015-05-28 Therapeutic tratment of skin disease with recombinant commensal skin microorganisms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020205127A Division JP2021038271A (ja) 2014-05-30 2020-12-10 組換え片利共生皮膚微生物による皮膚疾患の治療処置

Publications (3)

Publication Number Publication Date
JP2017518370A JP2017518370A (ja) 2017-07-06
JP2017518370A5 JP2017518370A5 (enExample) 2018-07-12
JP6810028B2 true JP6810028B2 (ja) 2021-01-06

Family

ID=54699800

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017515014A Active JP6810028B2 (ja) 2014-05-30 2015-05-28 組換え片利共生皮膚微生物による皮膚疾患の治療処置
JP2020205127A Pending JP2021038271A (ja) 2014-05-30 2020-12-10 組換え片利共生皮膚微生物による皮膚疾患の治療処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020205127A Pending JP2021038271A (ja) 2014-05-30 2020-12-10 組換え片利共生皮膚微生物による皮膚疾患の治療処置

Country Status (7)

Country Link
US (3) US10702558B2 (enExample)
EP (2) EP4144756A1 (enExample)
JP (2) JP6810028B2 (enExample)
CA (1) CA2979079A1 (enExample)
ES (1) ES2929579T3 (enExample)
MA (1) MA40057A (enExample)
WO (1) WO2015184134A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4144756A1 (en) 2014-05-30 2023-03-08 Azitra, Inc. Therapeutic treatment of skin disease with recombinant commensal skin microorganisms
AU2017254684A1 (en) 2016-04-21 2018-12-06 Weiss Bioscience, Inc. Compositions and methods for treatment of skin disorders
JP2020527357A (ja) * 2017-06-16 2020-09-10 アジトラ インコーポレーテッド Ｌｅｋｔｉ発現組換え微生物を用いたネザートン症候群の処置のための組成物および方法
EP3675884A4 (en) * 2017-08-31 2021-08-11 The Regents of the University of California MOLECULAR BACTERIOTHERAPY TO CONTROL ENZYMATIC ACTIVITY OF THE SKIN
WO2019050898A1 (en) * 2017-09-05 2019-03-14 Azitra Inc METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY SKIN DISEASE
JP7460531B2 (ja) 2017-12-05 2024-04-02 バイオピーエルエックス，インコーポレイティド 微生物感染を防ぐための方法および組成物
JP7121969B2 (ja) * 2018-02-23 2022-08-19 株式会社北里コーポレーション 培養液保護用液状物
AU2019249249B2 (en) 2018-04-05 2025-03-13 Azitra Inc Methods and compositions for treating skin disease with recombinant microorganisms
AU2019203692B2 (en) * 2018-08-30 2024-12-12 Kenvue Brands Llc Topical composition containing glycerin and yeast extract
US20210395775A1 (en) * 2018-09-26 2021-12-23 Krystal Biotech, Inc. Compositions and methods for the treatment of skin diseases
WO2020076770A1 (en) * 2018-10-08 2020-04-16 Yale University Selective binding and aggregation of human keratin in the skin barrier using human filaggrin subdomains sd67 and sd150
EP3880241A4 (en) * 2018-11-16 2022-08-17 Azitra, Inc. AUXOTROPHIC STRAINS OF STAPHYLOCOCCUS BACTERIA
CZ308231B6 (cs) * 2019-02-11 2020-03-11 BiomCare s.r.o. Kombinované několikastupňové mikrobiální přípravky a způsob jejich aplikace
CA3136115A1 (en) * 2019-04-05 2020-10-08 Azitra Inc Methods and compositions for treating atopic dermatitis with recombinant microorganisms
US20220362358A1 (en) * 2019-06-19 2022-11-17 Chan Zuckerberg Biohub, Inc. Bacteria-engineered to elicit antigen-specific t-cells
KR20220133262A (ko) * 2020-01-29 2022-10-04 더 잭슨 래보라토리 박테리아 혼합물
WO2022087065A1 (en) * 2020-10-21 2022-04-28 The Jackson Laboratory Antimicrobial biosensors
EP4274435A1 (en) * 2021-01-05 2023-11-15 Lactobio A/S Strains, compositions and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0637384B2 (ja) * 1985-09-21 1994-05-18 株式会社資生堂 皮膚化粧料
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
DE4221255C2 (de) 1992-06-26 1994-09-15 Lancaster Group Ag Phospholipide enthaltendes Kosmetikum
DE4221268C2 (de) 1992-06-26 1997-06-12 Lancaster Group Ag Verwendung eines Dermatikums zur Unterstützung des Sauerstofftransportes in der Haut
US20120295952A1 (en) * 2009-09-25 2012-11-22 Curna, Inc. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
AU2010321784B2 (en) 2009-11-23 2014-04-24 Research Development Foundation Recombinant filaggrin polypeptides for cell importation
US20130078275A1 (en) * 2010-05-25 2013-03-28 The Board Of Trustees Of The University Of Illinois Novel systems, vectors, and methods for delivery of biomolecules to eukaryotic cells
US9234204B2 (en) * 2012-08-07 2016-01-12 TopGeniX, Inc. Topical composition comprising transformed bacteria expressing a compound of interest
KR101491240B1 (ko) 2013-03-15 2015-02-11 현대자동차주식회사 인비저블 슬라이딩 도어 링크 구조
EP4144756A1 (en) 2014-05-30 2023-03-08 Azitra, Inc. Therapeutic treatment of skin disease with recombinant commensal skin microorganisms

Also Published As

Publication number Publication date
MA40057A (fr) 2015-12-03
US20210379120A1 (en) 2021-12-09
US20250009810A1 (en) 2025-01-09
JP2017518370A (ja) 2017-07-06
ES2929579T3 (es) 2022-11-30
EP3148569A1 (en) 2017-04-05
EP4144756A1 (en) 2023-03-08
WO2015184134A1 (en) 2015-12-03
CA2979079A1 (en) 2015-12-03
US10702558B2 (en) 2020-07-07
EP3148569B1 (en) 2022-07-06
EP3148569A4 (en) 2017-11-22
US12036248B2 (en) 2024-07-16
US20180161380A1 (en) 2018-06-14
JP2021038271A (ja) 2021-03-11

Similar Documents

Publication Publication Date Title
JP6810028B2 (ja) 組換え片利共生皮膚微生物による皮膚疾患の治療処置
KR102834865B1 (ko) 재조합 미생물을 사용하여 염증성 피부 질환을 치료하기 위한 방법 및 조성물
JP2023138994A (ja) Ｌｅｋｔｉ発現組換え微生物を用いたネザートン症候群の処置のための組成物および方法
US11850267B2 (en) Methods and compositions for treating skin disease with recombinant microorganisms
US20210070823A1 (en) Methods and compositions for treating atopic dermatitis with recombinant microorganisms
KR20230088803A (ko) 항미생물성 바이오센서
KR20230143154A (ko) 유전자 조작된 박테리아에서 단백질 발현을 증가시키기 위한 방법 및 조성물
HK1236133B (en) Therapeutic tratment of skin disease with recombinant commensal skin microorganisms
HK1236133A1 (en) Therapeutic tratment of skin disease with recombinant commensal skin microorganisms
WO2024118471A1 (en) Antimicrobial biosensors
JP2025504990A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ｅｐｉｄｅｒｍｉｄｉｓの染色体からのヒトｌｅｋｔｉ遺伝子の発現

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200910

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201210

R150 Certificate of patent or registration of utility model

Ref document number: 6810028

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250